GlobalData on MSN3d
Lynx Dx launches MPS2 prostate cancer test for at-home collection
The test can be ordered by physicians and is now qualified for Medicare reimbursement. MPS2 analyses a comprehensive set of 18 gene transcripts to predict the presence of clinical ...
Dynex Capital price target raised to $16 from $15 at BTIG
BTIG raised the firm’s price target on Dynex Capital (DX) to $16 from $15 and keeps a Buy rating on the shares. The firm’s price target hike ...
Brokerages Set Dynex Capital, Inc. (NYSE:DX) Target Price at $13.56
Dynex Capital, Inc. (NYSE:DX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that ...
TipRanks on MSN3d
Co-Diagnostics withdraws 510k application to FDA for Co-Dx PCR COVID-19 Test
Co-Diagnostics (CODX) announced that, following a collaborative and informative dialogue with the Food and Drug Administration, the company has ...
Dynex Capital raises quarterly dividend 13% to 17c per share
Inc. announced the Company’s Board of Directors has declared a cash dividend of $0.17 per share on its Common Stock for ...
Co-Dx撤回新冠检测试剂FDA申请，将开发升级版本
盐湖城 - 市值2,251万美元的分子诊断公司Co-Diagnostics, Inc. (NASDAQ: CODX )在与美国食品和药物管理局（FDA）讨论后，撤回了其Co-Dx™ PCR新冠检测试剂的510 (k)申请。此决定源于FDA对测试组件保质期稳定性的反馈。根据 InvestingPro 数据显示，该公司目前股价为$0.70，分析师预计本年度销售将下滑。
US tariffs will weaken dollar if nations strike back, Bank of America says
US President Donald Trump tariff policies will eventually be a drag on the dollar despite providing an initial boost, ...